Morgan Conn
Net worth: 163 278 $ as of 30/08/2026
Net worth: 163 278 $ as of 30/08/2026
Morgan Conn formerly worked at PTC Therapeutics, Inc., as Vice President-Business Development from 2001 to 2017, Amherst College, as Assistant Professor, Century Therapeutics, Inc., as Chief Financial Officer from 2024 to 2025, and Pharvaris NV, as Chief Business Officer from 2017 to 2024.
Dr. Conn received his doctorate degree from Massachusetts Institute of Technology and undergraduate degree from the University of Toronto.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 10/03/2025 | 79,648 ( 0.04% ) | 163 278 $ | 30/08/2026 |
| Companies | Position | End |
|---|---|---|
| CENTURY THERAPEUTICS, INC. | Director of Finance/CFO | 10/07/2025 |
| PHARVARIS N.V. | Corporate Officer/Principal | 03/10/2024 |
| PTC THERAPEUTICS, INC. | Corporate Officer/Principal | 31/12/2016 |
Amherst College
Amherst College Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 6 |
|---|---|
PTC Therapeutics, Inc.
PTC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets clinically differentiated medicines for neurodegenerative diseases | Health Technology |
Amherst College
Amherst College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
University of Toronto
University of Toronto Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pharvaris NV
Pharvaris NV BiotechnologyHealth Technology Develops and commercializes oral bradykinin B2 receptor antagonists | Health Technology |
Century Therapeutics, Inc.
Century Therapeutics, Inc. BiotechnologyHealth Technology Develops novel allogeneic living drugs for oncology that overcome the limitations of first-generation cell therapies | Health Technology |
Select your edition
All financial news and data tailored to specific country editions